Brian Posner Acquires 3,000 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Brian Posner bought 3,000 shares of the business’s stock in a transaction that occurred on Friday, March 6th. The stock was purchased at an average cost of $15.06 per share, with a total value of $45,180.00. Following the purchase, the director directly owned 11,500 shares in the company, valued at $173,190. The trade was a 35.29% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Dyne Therapeutics Trading Up 11.8%

NASDAQ:DYN traded up $2.09 on Tuesday, reaching $19.78. The stock had a trading volume of 5,746,914 shares, compared to its average volume of 2,182,854. Dyne Therapeutics, Inc. has a 12-month low of $6.36 and a 12-month high of $25.00. The company has a market cap of $3.26 billion, a price-to-earnings ratio of -5.59 and a beta of 1.34. The firm’s fifty day moving average is $17.01 and its two-hundred day moving average is $17.15. The company has a debt-to-equity ratio of 0.15, a current ratio of 22.25 and a quick ratio of 22.25.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Monday, March 2nd. The company reported ($0.76) EPS for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). Equities analysts expect that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on DYN shares. JPMorgan Chase & Co. cut their price target on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday, January 20th. Robert W. Baird set a $30.00 price objective on Dyne Therapeutics in a report on Monday, December 8th. Morgan Stanley lowered their price objective on Dyne Therapeutics from $50.00 to $47.00 and set an “overweight” rating for the company in a research report on Monday, March 2nd. Raymond James Financial reiterated a “strong-buy” rating and issued a $40.00 target price on shares of Dyne Therapeutics in a research note on Monday, December 8th. Finally, Evercore reduced their target price on Dyne Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a research report on Monday, December 15th. Three analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $36.13.

Key Dyne Therapeutics News

Here are the key news stories impacting Dyne Therapeutics this week:

• Positive Sentiment: Company reported new positive cardiopulmonary results from the DELIVER trial (z‑rostudirsen / DYNE‑251), which analysts and press framed as strengthening the DMD (Duchenne) therapeutic thesis — this data release is a direct clinical catalyst that can materially lift valuation if it supports later‑stage success. CALENDONIAN RECORD
• Positive Sentiment: Dyne announced initiation of the pivotal Phase III HARMONIA trial for DYNE‑101 (DM1), a clear regulatory/value inflection point that de‑risks the program and can drive re‑rating if enrollment and endpoints progress as expected. Yahoo News
• Positive Sentiment: Chardan Capital reaffirmed a “buy” rating and set a $38 price target, implying substantial upside vs. current levels — analyst support like this can attract momentum buyers and institutional interest. Benzinga
• Positive Sentiment: Insider buying: Director Brian S. Posner purchased 3,000 shares at about $15.06, increasing his stake ~35% — insider purchases are often interpreted as a bullish signal on management’s confidence. SEC Filing
• Positive Sentiment: Bull‑case commentary and analyst writeups highlight Dyne’s ~ $1.1B cash runway into mid‑2028 and view the DELIVER/HARMONIA catalysts as value drivers — financial runway reduces near‑term dilution risk and supports program execution. Seeking Alpha
• Neutral Sentiment: Reported short interest entries show zero shares and a 0.0 days‑to‑cover metric — either indicating minimal short pressure or data/reporting anomalies; this reduces the chance of a short‑squeeze dynamic but may reflect noisy data. (No article link)

Institutional Trading of Dyne Therapeutics

Institutional investors have recently made changes to their positions in the stock. T. Rowe Price Investment Management Inc. increased its holdings in shares of Dyne Therapeutics by 523.7% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 17,540,089 shares of the company’s stock worth $343,085,000 after buying an additional 14,727,667 shares during the last quarter. Vanguard Group Inc. boosted its holdings in Dyne Therapeutics by 14.9% in the fourth quarter. Vanguard Group Inc. now owns 11,215,565 shares of the company’s stock valued at $219,376,000 after acquiring an additional 1,455,151 shares during the last quarter. State Street Corp boosted its holdings in Dyne Therapeutics by 27.0% in the fourth quarter. State Street Corp now owns 6,692,745 shares of the company’s stock valued at $130,910,000 after acquiring an additional 1,423,828 shares during the last quarter. Adage Capital Partners GP L.L.C. grew its position in Dyne Therapeutics by 45.5% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 5,172,000 shares of the company’s stock valued at $101,164,000 after acquiring an additional 1,618,000 shares during the period. Finally, Orbis Allan Gray Ltd purchased a new stake in Dyne Therapeutics during the fourth quarter valued at about $93,926,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.